Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0002736 (
amyotrophic lateral sclerosis
)
19,048
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Sialorrhoea is a socially disabling problem in bulbar
amyotrophic lateral sclerosis
(
ALS
). Botulinum toxin A (
BoNT/A
) was injected into the salivary glands in five patients with bulbar
ALS
and sialorrhoea. The effect of
BoNT/A
was measured by the number of paper handkerchiefs used each day and by salivary gland scintigraphy.
BoNT/A
ameliorated sialorrhoea and quality of life without major adverse effects.
BoNT/A
may be a relatively safe and effective treatment for sialorrhoea in selected patients.
...
PMID:Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. 1124 5
Botulinum neurotoxin serotype A (
BoNT/A
) has revolutionised the treatment of a variety of autonomic hypersecretory disorders. Several open and controlled studies indicate that
BoNT/A
is a safe and effective treatment for focal hyperhidrosis of the axillae and palms, for gustatory sweating, and for some other rare conditions associated with focal hyperhidrosis. There is class I evidence for the efficacy of botulinum toxin in axillary hyperhidrosis and class II evidence for palmar hyperhidrosis and gustatory sweating.
BoNT/A
has the potential to replace current invasive and surgical techniques and should at least be considered as a viable alternative. The results of pilot studies to treat sialorrhea are encouraging. However, the optimal dose, best mode of application, side effects, and duration of
BoNT/A
action in this condition remain uncertain. We need further formal clinical trials to evaluate risks and benefits of
BoNT/A
for palliative treatment in of sialorrhea in Parkinson's disease and in bulbar
amyotrophic lateral sclerosis
. Based on the few reports published,
BoNT/A
injections into the lacrimal gland for hyperlacrimation may be an elegant method to treat this sometimes disabling condition. Again, larger studies are needed to evaluate the risks and long-term benefits of this treatment option.
...
PMID:Botulinum toxin treatment of secretory disorders. 1502 66
Botulinum toxin type A (
BoNT/A
) has been proposed as an alternative treatment for sialorrhoea in patients with
amyotrophic lateral sclerosis
(
ALS
). In an open-label prospective study,
BoNT/A
was injected into the parotid glands bilaterally using anatomic landmarks in 26
ALS
patients with bulbar symptoms. Two weeks after injection the severity of sialorrhoea and the related disability were evaluated subjectively and objectively. A group of healthy subjects acted as controls for saliva production. Patients also underwent electrophysiological tests to evaluate possible toxin effects in the nearby non-injected muscles by comparing the amplitude of compound motor action potentials (cMAPs) elicited by electrical stimulation and recorded from the orbicularis oculi and masseter muscles. After
BoNT/A
injections, of the 26 patients treated, 23 reported that the severity of sialorrhoea improved and the disabling symptoms diminished. Cotton roll weight also decreased after
BoNT/A
injection, suggesting a reduction in saliva production. Two patients complained of dry mouth.
BoNT/A
injection left the cMAP amplitude unchanged, suggesting that botulinum toxin does not significantly affect the non-injected facial and masticatory muscles. In conclusion, intraparotid anatomically-guided
BoNT/A
injection is an effective, easy, and safe treatment for sialorrhoea in patients with bulbar symptoms related to
ALS
.
...
PMID:Botulinum toxin type A for the treatment of sialorrhoea in amyotrophic lateral sclerosis: a clinical and neurophysiological study. 1992 45
